Education ▼

SPECIALTY TOPICS

CURRENTLY VIEWING
Mantle Cell Lymphoma

Breast Cancer

Gastrointestinal Cancer

Colorectal Cancer

Ovarian Cancer

Prostate Cancer

Precision Medicine in Oncology^®

Neoadjuvant HER2+

More >>

Mantle Cell Lymphoma

FDA Grants Zanubrutinib Priority Review for Relapsed/Refractory Mantle Cell Lymphoma

$FDA Grants Zanubrutinib Priority Review for Relapsed/Refractory Mantle Cell Lymphoma$

The FDA has granted a priority review designation to a new drug application for zanubrutinib for the treatment of patients with mantle cell lymphoma who have received ≥1 prior therapy.
Read More >>

Expert Reflects on Rapidly Evolving Field of MCL

Mantle Cell Lymphoma Options Expand, With CAR-T on the Horizon

Frontline Mantle Cell Lymphoma Treatment Must Involve Personalized Approach

Zanubrutinib Continues to Show Encouraging Activity in Relapsed/Refractory MCL

Rituximab Regimen Elicits High ORR in Relapsed MCL

View More Stories >>

View Conference Coverage

Charlotte Plasma Cell Disorder Congress

State of the Science Summit on Breast Cancer in Long Island

2019 International Lung Cancer Congress

2019 State of the Science Summit on Genitourinary Cancers in Jacksonville

2019 State of the Science Summit on Hematologic Malignancies in Pittsburgh

Dr. Martin on Ibrutinib/Palbociclib Combo in Ibrutinib-Resistant MCL

Dr. Rule on the Treatment Paradigm in MCL

Dr. Rule on Standard of Care in MCL

Dr. Rule on the Combination of Venetoclax and Ibrutinib in MCL

Dr. Karmali on Next Steps of Research Regarding Ibrutinib Maintenance in MCL

Dr. McCulloch on the Use of R-BAC in MCL After Progression on BTK Therapy

OncLive houses thousands of videos that provide updates and information.
See more Videos

Practical Advice on the Future Management of MCL

R/R MCL: Synchronizing Older and Newer Therapeutic Strategies

$Selection of a BTK Inhibitor in Relapsed/Refractory MCL$

Selection of a BTK Inhibitor in Relapsed/Refractory MCL

Mantle Cell Lymphoma: An Overview on Frontline Therapy

Highlights from ASH 2017: Mantle Cell Lymphoma

Investigational Treatment in Mantle Cell Lymphoma

Future Therapy: Bruton's TKI Containing Combinations in MCL

OncLive houses thousands of videos that provide updates and information.
See more Videos

New and Emerging BTK Inhibitors in Mantle Cell Lymphoma

First-Generation BTK Inhibition in Mantle Cell Lymphoma

Advice for Future Management of Mantle Cell Lymphoma

Non-BTKi Agents' Role in Mantle Cell Lymphoma

MCL: Novel BTK Inhibitor Combination Strategies

$Identifying Unmet Needs in Relapsed/Refractory MCL$

Differentiating BTK Inhibitor Mechanisms of Action in MCL

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured Programs

Ibrutinib in Relapsed Mantle Cell Lymphoma

Drs Danilov, Goy, Leonard, Pagel, and Schuster, discuss ibrutinib (Imbruvica) as a treatment in relapsed mantle cell lymphoma. View Now

Treatments for Relapsed Mantle Cell Lymphoma

Brad S. Kahl, MD, and Richard R. Furman, MD, explain available treatment options for relapsed mantle cell lymphoma. View Now

Featured Video

Dr. Richardson Discusses New Directions in Multiple Myeloma

Paul G. Richardson, MD, clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center, and institute physician, Dana-Farber Cancer Institute, discusses new directions in multiple myeloma. View now

Priority Review Designation in GIST, Promising Findings in Bladder Cancer and NSCLC, and More